Health Care/Hospital
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...
2021-06-18 17:12
13539
RBC Expands Global Youth Charity Program - RBC Charity Day for the Kids
* Virtual celebrations held by RBC Capital Markets employees in Canada, U.S., U.K.,France, Germany, Japan, Hong Kong, Australia, Barbados and Bahamas * US$5 million donated to over 50 charities worldwide SYDNEY, June 18, 2021 /PRNewswire/ -- As part of a global charitable initiative called RBC...
2021-06-17 20:00
1562
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
2021-06-17 15:41
13603
Waterdrop Inc. Announces First Quarter 2021 Unaudited Financial Results
BEIJING, June 17, 2021 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the first quarter endedMarch 31, 2...
2021-06-17 15:05
22071
InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma
BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...
2021-06-17 11:31
13971
Spark™ Aligners Receive FDA Clearance For Orthodontic Treatment Of Kids, Giving Parents A New Option With Significant Treatment Advantages Over The Leading Competitor
-- Newest Doctor-Directed Clear Aligner System For Straightening Teeth Now TreatsYounger Patients with Both Primary & Secondary Teeth with Simple to Complex Orthodontic Issues -- BREA, Calif., June 16, 2021 /PRNewswire/ -- Ormco Corporation, a global leader of orthodontic solutions, today announ...
2021-06-16 21:05
2004
Spark Aligners Does It Again With Market Leading Innovation And New FDA Approval To Give Doctors Greater Control And Flexibility
-- New Features in Release 11 Combined with Expanded Indication for Mixed Dentition to Treat Kids and Teens is a Home Run for Doctors -- BREA, Calif., June 16, 2021 /PRNewswire/ -- Ormco Corporation, a global leader of orthodontic solutions, today announced it has received FDA clearance to tre...
2021-06-16 20:45
1394
SMIC Liver Transplant Program's Ninth Donation Raised Over 33 Million Yuan
SHANGHAI, June 16, 2021 /PRNewswire/ -- On June 16th, Semiconductor Manufacturing International Corporation held its 9th SMIC Liver Transplant Program Donation Ceremony at Shanghai Jiao Tong University School of Medicine's Renji Hospital. As of this year, SMIC has cumulatively raised over33 milli...
2021-06-16 17:48
7529
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...
2021-06-16 13:08
8275
Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci
SHANGHAI, June 15, 2021 /PRNewswire/ -- Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human ...
2021-06-16 10:14
22331
Smith+Nephew launches Real Intelligence and CORI™ Surgical System, next generation robotics platform, in Australia and New Zealand
LONDON, June 16, 2021 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its Real Intelligence suite of enabling technology solutions including its next generation robotics platform, the CORI Surgical System, inAustralia and New ...
2021-06-16 06:00
11273
VNTC confirms Dong-A ST its sole distributor of scoliosis brace Spinamic in South Korea
SEOUL, South Korea, June 15, 2021 /PRNewswire/ -- VNTC, a MedTech company, announced onJune 15 its signing of a Korean distributorship contract with Dong-A ST. The two companies are now able to provide a wide range of services both at home and abroad through mutual cooperation in sales and market...
2021-06-16 00:00
2446
Frontera Therapeutics Starts GMP Manufacturing Facility Construction
SUZHOU, China, June 15, 2021 /PRNewswire/ -- On June 9, 2021, Frontera Therapeutics Co., Ltd. ('Frontera') held a groundbreaking ceremony to start the construction of its Suzhou facility in bioBAY of Suzhou Industrial Park (SIP), Jiangsu, China. President of Suzhou Frontera, Dr. Xinyan Li, hosted ...
2021-06-15 23:32
1549
BIO Digital Taiwan Day will be held on June 22
TAIPEI, June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt their practices and embrace digital transformation - and now, as vaccines become more available in the developed countries, it is time to look into the future...
2021-06-15 23:00
1470
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with theJoan & Sanford I Weill Medical College of Cornell University in the United States, to launch ...
2021-06-15 22:00
10973
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...
2021-06-15 08:46
1231
Happiness Biotech Signed Agreement To Distribute Volkswagen Electric Vehicles
NANPING, China, June 14, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...
2021-06-14 20:00
10725
Chinese biotech firm Vazyme to showcase full range of COVID-19 Testing Solutions at Medlab
DUBAI, UAE, June 14, 2021 /PRNewswire/ -- Chinese biotechnology company Vazyme will showcase a rich lineup of products at the 2021 Medlab Middle East, a leading medical laboratory exhibition co-located with Arab Health. The live in-person event is scheduled to take place from 21 to24 June, 2021 a...
2021-06-14 15:00
1732
Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis
SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...
2021-06-14 06:00
1903
ImmVira completed the first dosing for Phase II of MVR-T3011 (intratumoral injection) in the U.S. and China
SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in bothChina and the U.S. on May 28 2021 and June 11 20...
2021-06-12 11:16
3006
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 276 media titles]
2024-04-19 13:25
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3814
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3081
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
2972
